William Pickering
Stock Analyst at Bernstein
(3.14)
# 2,611
Out of 4,651 analysts
217
Total ratings
61.2%
Success rate
3.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $572 → $608 | $505.75 | +20.22% | 31 | Aug 11, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Rated: Hold | $35 → $46 | $86.64 | -46.91% | 9 | May 13, 2026 | |
| NTLA Intellia Therapeutics | Rated: Hold | $13 → $17 | $11.91 | +42.74% | 14 | May 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $50 → $56 | $53.55 | +4.58% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Rated: Buy | $40 → $39 | $26.75 | +45.79% | 18 | May 13, 2026 | |
| DYN Dyne Therapeutics | Rated: Hold | $23 → $24 | $25.70 | -6.61% | 7 | May 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 → $114 | $79.86 | +42.75% | 4 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $94 → $82 | $67.34 | +21.77% | 21 | May 5, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $451 → $447 | $228.65 | +95.50% | 20 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Hold | $3.85 | $2.05 | +87.80% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $916 → $921 | $803.48 | +14.63% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $18.10 | +10.50% | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 | $41.82 | -33.05% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $36.20 | -3.31% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $157 → $201 | $209.83 | -4.21% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $89 | $57.24 | +55.49% | 22 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 → $9 | $14.64 | -38.52% | 12 | Nov 6, 2025 |
Vertex Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $572 → $608
Current: $505.75
Upside: +20.22%
Arrowhead Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $35 → $46
Current: $86.64
Upside: -46.91%
Intellia Therapeutics
May 13, 2026
Rated: Hold
Price Target: $13 → $17
Current: $11.91
Upside: +42.74%
CRISPR Therapeutics AG
May 13, 2026
Rated: Hold
Price Target: $50 → $56
Current: $53.55
Upside: +4.58%
Beam Therapeutics
May 13, 2026
Rated: Buy
Price Target: $40 → $39
Current: $26.75
Upside: +45.79%
Dyne Therapeutics
May 13, 2026
Rated: Hold
Price Target: $23 → $24
Current: $25.70
Upside: -6.61%
BridgeBio Pharma
May 8, 2026
Reiterated: Buy
Price Target: $100 → $114
Current: $79.86
Upside: +42.75%
BioMarin Pharmaceutical
May 5, 2026
Rated: Buy
Price Target: $94 → $82
Current: $67.34
Upside: +21.77%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $451 → $447
Current: $228.65
Upside: +95.50%
Allogene Therapeutics
Apr 14, 2026
Maintained: Hold
Price Target: $3.85
Current: $2.05
Upside: +87.80%
Apr 8, 2026
Maintained: Buy
Price Target: $916 → $921
Current: $803.48
Upside: +14.63%
Mar 25, 2026
Maintained: Hold
Price Target: $20
Current: $18.10
Upside: +10.50%
Mar 20, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $41.82
Upside: -33.05%
Mar 20, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $36.20
Upside: -3.31%
Feb 6, 2026
Maintained: Hold
Price Target: $157 → $201
Current: $209.83
Upside: -4.21%
Jan 13, 2026
Maintained: Hold
Price Target: $65 → $89
Current: $57.24
Upside: +55.49%
Nov 6, 2025
Downgraded: Hold
Price Target: $34 → $9
Current: $14.64
Upside: -38.52%